%20Tabletsabiraterone%20acetate%20tablets,%20250%20mg%20film-coated%20tablets,500%20mg%20film-coated%20tablets,%20prostate%20cancer%20treatment,%20Abirataj%20Taj%20pharma_prostate-cancer.jpg)
%20Tabletsabiraterone%20acetate%20tablets,%20250%20mg%20film-coated%20tablets,500%20mg%20film-coated%20tablets,%20prostate%20cancer%20treatment,%20Abirataj%20Taj%20pharma_%20250%20mg%20film-coated%20tab.jpg)
%20Tabletsabiraterone%20acetate%20tablets,%20250%20mg%20film-coated%20tablets,500%20mg%20film-coated%20tablets,%20prostate%20cancer%20treatment,%20Abirataj%20Taj%20pharma_%20250%20mg%20film-.jpg)
prd1.jpg)
prd2.jpg)
prd3.jpg)
prd5.jpg)
prd6.jpg)
prd7.jpg)
prd8.jpg)
Abirataj is indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC)
read moreRecommended Dose For Metastatic CRPC
The recommended dose of abirataj is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg orally twice daily.
Like all medicines, this medicine can cause side effects, although not everybody gets them.. Stop taking Abiraterone Acetate Tablet and see a doctor immediately if you notice any of the following side effects.
read moreDrugs That Inhibit Or Induce CYP3A4 Enzymes
In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%.
Abirataj may cause hypertension, hypokalemia, and fluid retention increased mineralocorticoid levels resulting from CYP17 inhibition.Monitor patients for hypertension, hypokalemia, and fluid retention at least once a month.
read moreMechanism Of Action
Abiraterone acetate (Abirataj) is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17).
Life is the underlying purpose of everything we do at Taj Pharma Group. We are committed to developing a distinguished generics pharmaceuticals business.
Taj Pharma is one of the leading generic pharmaceutical company in India. We hold top positions in different established markets and gradually building a strong presence in many emerging generics markets. We have eight manufacturing sites under flagship in India to support our market standing.
prd1.jpg)
prd2.jpg)
prd3.jpg)
prd4.jpg)
prd5.jpg)
prd6.jpg)
prd7.jpg)
prd8.jpg)